接受阿替普酶治疗的急性缺血性卒中患者使用降压药的影响
该研究为多中心回顾性队列,纳入2011—2015年>18岁、接受阿替普酶的急性缺血性卒中患者,比较发病/用药后24小时内使用降压药者与未使用者。351例中127例(36.2%)使用了降压药,最常用为拉贝洛尔静脉推注(81.2%),其次尼卡地平(44.1%)、肼屈嗪(22%)。单因素分析显示降压组90天mRS≥3比例更高(53.5% vs 38.8%,p<0.01),但多因素logistic回归校正后该关联不再存在。提示不能据此把早期降压本身判为有害,床旁决策仍需个体化。
要点
- 单因素:阿替普酶后24小时内用降压药者90天mRS≥3为53.5%,未用者38.8%(p<0.01)。
- 多因素logistic回归校正其他临床因素后,早期使用降压药与90天不良神经结局的关联不再存在。
- 降压组高血压病史(88.2% vs 69.6%)、糖尿病(37% vs 25.5%)、慢性肾病(19.7% vs 8.5%)比例均更高。
- 最常用降压药为拉贝洛尔静脉推注(81.2%),其次尼卡地平(44.1%)、肼屈嗪(22%)。
- 研究为回顾性队列,仅提示关联,不能作为早期降压或停降压的因果依据。
适用人群与场景
- >18岁、诊断为急性缺血性卒中并接受阿替普酶治疗的患者,来自2011年1月1日至2015年12月31日的多中心回顾性队列。
- 暴露组为卒中后/阿替普酶后24小时内接受一种或多种降压药者,对照组为未使用者;原文未给出其他纳入或排除标准。
诊断标准与关键阈值
- 主要终点为90天不良神经结局,定义为改良Rankin量表(mRS)≥3。
- 原文未提及血压启动降压的具体阈值或目标值。
处置流程与药物剂量
- 原文未提及按血压阈值启动降压的具体流程或目标值;文中记录的实际用药为:拉贝洛尔静脉推注(81.2%)、尼卡地平(44.1%)、肼屈嗪(22%)。
- 上述药物剂量、输注速度、频次及疗程原文均未提及。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:多中心回顾性队列;共评估587例,最终纳入351例,其中127例(36.2%)在24小时内使用降压药。
- 主要终点:降压组90天mRS≥3为53.5%,对照组为38.8%(p<0.01),但多因素logistic回归校正后该关联不再存在。
- 基线差异:降压组高血压病史88.2% vs 69.6%(p<0.01)、糖尿病37% vs 25.5%(p=0.03)、慢性肾病19.7% vs 8.5%(p<0.01)。
- 用药构成:静脉推注拉贝洛尔81.2%、尼卡地平44.1%、肼屈嗪22%。
证据类型、等级与局限
- 证据类型:多中心回顾性队列研究。
- 局限:回顾性设计、样本量351例、仅观察24小时内降压药使用与90天结局的关联,多因素校正后关联消失,提示存在混杂。
对床旁实践的改变
- 不能仅凭单因素结果(53.5% vs 38.8%)把阿替普酶后24小时内使用降压药判定为导致不良结局的原因,多因素校正后关联消失。
- 原文未提供血压阈值或目标值,故本内容不改变具体的降压启动阈值或目标血压设定。
- 对合并高血压、糖尿病、慢性肾病的阿替普酶患者,早期降压决策需结合个体情况,不能据本文推断停药或积极降压的获益。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Treatment of acute ischemic stroke (AIS) with intravenous alteplase within 4.5 h of symptom onset is associated with neurologic improvement. High baseline blood pressure (BP) and BP variability during the first 24 h of AIS is associated with increased early adverse events and death. The purpose of this study is to characterize the incidence of poor neurologic outcome in patients treated with alteplase for AIS who received antihypertensive medications prior to and within the first 24 h following alteplase administration compared with patients who did not.
METHODS: This was a multicenter, retrospective cohort of patients >18 years diagnosed with AIS from January 1, 2011 through December 31, 2015 who received one or more antihypertensive medication in the first 24 h of AIS in patients receiving alteplase compared to controls. The primary endpoint was poor neurologic outcome at 90 days, according to modified Rankin Scale ≥3. Univariate analysis was conducted using Chi-square, Fisher's exact test, or Mann-Whitney U test. Multivariable logistic regression was conducted to determine independent predictors of poor outcome.
RESULTS: Of the 587 patients evaluated, 351 (59.7%) were included, of which 127 (36.2%) received antihypertensive(s). More patients in the antihypertensive treatment group had a history of hypertension (88.2% vs. 69.6%, p < 0.01), diabetes (37% vs. 25.5%, p = 0.03) and chronic kidney disease (19.7% vs. 8.5%, p < 0.01). Intravenous push labetalol was most commonly administered (81.2%), followed by nicardipine (44.1%), and hydralazine (22%). More patients in the antihypertensive treatment group experienced poor neurologic outcome at 90 days (53.5% vs. 38.8%, p < 0.01), however, this finding was not observed after multivariable logistic regression.
CONCLUSION: Antihypertensive treatment in the first 24 h of AIS was associated with poor neurologic outcomes at 90 days. However, after controlling for other clinical factors in a multivariable logistic regression, this association was no longer observed.
参考来源
- Rech MA, Donahey E, DeMott JM, et al. The impact of antihypertensive use in the treatment of acute ischemic stroke in patients receiving alteplase. Am J Emerg Med. 2021. PMID: 34329955. doi:10.1016/j.ajem.2021.07.037
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。